AB
Aspire Biopharma Holdings Inc. is developing a nanotechnology-based drug formulation that directly targets pain and inflammation while bypassing the gastrointestinal tract. This approach aims to provide effective pain relief with a reduced risk of addiction, addressing the challenges posed by traditional opioid medications.
Updated 3 months ago
Funding
$220K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Aspire Biopharma Holdings Inc. is developing a nanotechnology-based drug formulation that directly targets pain and inflammation while bypassing the gastrointestinal tract. This approach aims to provide effective pain relief with a reduced risk of addiction, addressing the challenges posed by traditional opioid medications.